1788P Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial
K. Chang,X. Zhang,L. Xie,S. Wang,B. Shi,T. Sun,S. Wei,Z. Weng,S. Xia,B. Han,Z. Xu,J. Xing,D. Zhang,D. Xu,C. Du,C. He,Q. Wang,J. Lian,Q. Shi,D. Ye
DOI: https://doi.org/10.1016/j.annonc.2023.09.2738
IF: 51.769
2023-01-01
Annals of Oncology
Abstract:CHART trial has demonstrated the survival benefit of rezvilutamide plus androgen deprivation therapy (ADT) over bicalutamide plus ADT in treating patients with high-volume, metastatic hormone-sensitive prostate cancer (mHSPC). This post-hoc analysis aimed to evaluate the association between achievement of deep PSA decline with survival outcomes in patients with high-volume mHSPC in the CHART trial. Patients with high-volume mHSPC were randomly assigned (1:1) to receive ADT plus either rezvilutamide or bicalutamide. PSA kinetics and the association between deep PSA decline (≤0.2 ng/ml) and radiographic progression-free survival (rPFS) and overall survival (OS) in two groups were evaluated. A total of 654 patients were included in the analysis, with 326 patients in the rezvilutamide plus ADT group, and 328 patients in the bicalutamide plus ADT group. The median PSA nadir levels were 0.02 ng/ml, and 0.68 ng/ml in two groups, respectively. At 6-month, 170 (52.15%) and 90 (27.44%) patients achieved a deep PSA decline, respectively. With a median follow-up of 29.3 months, patients who achieved a deep PSA decline at 6-month had longer rPFS (HR=0.359, 95%CI 0.238, 0.543, P<0.001) and OS (HR=0.339, 95%CI 0.212, 0.540, P<0.001) than those who did not achieve it in the rezvilutamide plus ADT group. Significantly, rezvilutamide plus ADT was found to significantly prolong rPFS compared to bicalutamide plus ADT, regardless of whether patients achieved deep PSA decline at 6-month (HR=0.462, 95%CI 0.283, 0.754, P=0.002) or not (HR=0.587, 95%CI 0.428, 0.804, P<0.001).Table: 1788PPSA kinetics in CHART trialVariablesRezvilutamide plus ADT (n=326)Bicalutamide plus ADT (n=328)PSA baseline (ng/ml), median (Q1, Q3)78.79 (12.82, 314.80)51.32 (8.08, 236.63)PSA nadir (ng/ml), median (Q1, Q3)0.02 (0.00, 0.41)0.68 (0.08, 3.16)Time to PSA nadir, day, median (Q1, Q3)308.0 (169.0, 634.8)167.0 (85.0, 281.0)PSA nadir ≤0.2 ng/ml, n (%)224 (68.7)109 (33.2)Time to PSA ≤0.2 ng/ml, day, median (Q1, Q3)392.0 (222.3, 671.0)238.0 (141.0, 393.0)PSA ≤0.2 ng/ml at 3-month, n (%)125 (38.34)58 (17.68)PSA ≤0.2 ng/ml at 6-month, n (%)170 (52.15)90 (27.44)PSA ≤0.2 ng/ml at 12-month, n (%)201 (61.66)108 (32.93) Open table in a new tab Rezvilutamide plus ADT resulted in a deep PSA decline, which was associated with improved long-term survival in patients with high-volume mHSPC.